[Sucralfate].
Hiraishi
Hideyuki
H
Department of Gastroenterology, Dokkyo University School of Medicine.
Kanke
Kazunari
K
Terano
Akira
A
D000897:Anti-Ulcer Agents / Q000494:pharmacology / Q000627:therapeutic use; D017291:Clarithromycin / Q000627:therapeutic use; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D005744:Gastric Acid / Q000378:metabolism; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects / Q000201:enzymology; D006801:Humans; D008795:Metronidazole / Q000627:therapeutic use; D009853:Omeprazole / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000188:drug therapy / Q000209:etiology; D013392:Sucralfate / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome; D014510:Urease / Q000037:antagonists & inhibitors
D000897:Anti-Ulcer Agents; D008795:Metronidazole; D013392:Sucralfate; D014510:Urease; D017291:Clarithromycin; D009853:Omeprazole